Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5582/ddt.2020.03006 http://scihub22266oqcxt.onion/10.5582/ddt.2020.03006 32378647!ä!32378647 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Drug+Discov+Ther 2020 ; 14 (2): 100-102 Nephropedia Template TP {{tp|p=32378647|t=2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?|pdf=|usr=}}{{32378647}} gab.com Text Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far JO: Drug Discov Ther http://www.kidney.de/pget.php?&tw=1&pmid=32378647 #FOAvip The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of "cytokine storm" in COVID-19. However, we still lack reliable studies to verify "cytokine storm" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated. Twit Text FOAVip Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far ????Drug Discov Ther http://www.kidney.de/pget.php?&tw=1&pmid=32378647 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32378647 #FOAvip English Wikipedia <ref>{{Cite pmid|32378647}}</ref> Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? #MMPMID32378647 Zhang Y; Zhong Y; Pan L; Dong J Drug Discov Ther 2020[]; 14 (2): 100-102 PMID32378647show ga The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of "cytokine storm" in COVID-19. However, we still lack reliable studies to verify "cytokine storm" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated. |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/*drug therapy[MESH] |Cytokines/adverse effects[MESH] |Humans[MESH] |Interleukin-6[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Receptors, Interleukin-6/*antagonists & inhibitors[MESH]Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we al(epmc).pdf DeepDyve Pubget Overpricing